Abstracts tagged "anti-CCP antibodies"

Abstract Number: 1200 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies in Idiopathic Pulmonary Fibrosis Are Not Citrulline-Specific: Implications for the Pathogenesis of Rheumatoid Arthritis
Elena B. Lugli¹, Muslima Chowdhury¹, Peter J. Charles², Michael G. Crooks³, Simon P. Hart³, Patrick Venables¹ and Benjamin A. Fisher⁴, ¹Kennedy Institute of Rheumatology, Oxford University, London, United Kingdom, ²Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ³Castle Hill Hospital, Hull York Medical School, Cottingham, United Kingdom, ⁴Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: The association of rheumatoid arthritis (RA) with smoking and silica exposure has led to the hypothesis that the lung is the site where RA autoimmunity…
Abstract Number: 1208 • 2012 ACR/ARHP Annual Meeting
Stable Synovial Fluid Phenotype for Anti Citrullinated-Protein Antibodies in Established Rheumatoid Arthritis
Vijay Joshua¹, Lena Israelsson², Lars Klareskog³, Anca Catrina¹ and Vivianne Malmström⁴, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Department of Medicine, Karolinska Institute, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Presence of anti citrullinated-protein antibodies (ACPA) in the peripheral blood of patients with rheumatoid arthritis is a validated disease biomarker. We have previously shown…
Abstract Number: 2615 • 2012 ACR/ARHP Annual Meeting
Circulating Levels of Citrullinated Vimentin Fragments Are Diagnostic and Prognostic in Ankylosing Spondylitis; Evidence for Disease-Related Citrullination
Anne C. Bay-Jensen¹, Morten Asser Karsdal², Efstathios Vassiliadis³, Stephanie Wichuk⁴, Zheng Zhao⁵, Robert GW Lambert⁶, Rik Lories⁷, Claus Christiansen⁸ and Walter P. Maksymowych⁹, ¹Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ²Nordic Bioscience A/S, Herlev, Denmark, ³Nordic Bioscience, Herlev, Denmark, ⁴Medicine, University of Alberta, Edmonton, AB, Canada, ⁵Department of Rheumatology, University of Alberta and PLA General Hospital, Beijing, PR China, Beijing, AB, China, ⁶Radiology, University of Alberta, Edmonton, AB, Canada, ⁷Laboratory of Tissue Homeostasis and Disease - SBE Research Center, KU Leuven, Leuven, Belgium, ⁸CCBR, Ballerup, Denmark, ⁹Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Rheumatoid arthritis (RA) is considered an anti-CCP positive disease whereas ankylosing spondylitis (AS) is considered an anti-CCP negative disease. Anti-CCP has prognostic capacity in…
Abstract Number: 1211 • 2012 ACR/ARHP Annual Meeting
ANTI-Cyclic Citrullinated Protein Antibodies Induce Inflammation and Oxidative Stress in WHITE Blood CELLS of Rheumatoid Arthritis Patients
Chary Lopez-Pedrera¹, Carlos Perez-Sanchez¹, Patricia Ruiz-Limon¹, Mª Angeles Aguirre², Rosario M. Carretero-Prieto¹, Antonio Rodriguez-Ariza³, Nuria Barbarroja¹, Pilar Font¹, Francisco Martinez², Inmaculada Gomez-Gracia², Mª Jose Cuadrado⁴ and Eduardo Collantes-Estevez², ¹Rheumatology Unit, IMIBIC-Reina Sofia University Hospital, Cordoba, Spain, ²Rheumatology, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ³Oncology Service and Research Unit, IMIBIC-Reina Sofia Hospital, Cordoba, Spain, ⁴Lupus Research Unit, The Rayne Institute, London, United Kingdom
Background/Purpose: Anti-cyclic citrulinated protein antibodies (anti-CCP) are the most specific autoantibody markers in rheumatoid arthritis (RA) patients. However no previous studies have evaluated their role…
Abstract Number: 2581 • 2012 ACR/ARHP Annual Meeting
Anti- Citrullinated Protein Antibodies but Not Rheumatoid Factor Are Associated with Larger Bone Erosions in rheumatoid arthritis patients- a Cross-Sectional Micro Computed Tomography Study
Carolin Hecht¹, Stephanie Finzel¹, Matthias Englbrecht¹, Sarah Schmidt¹, Juergen Rech², Elizabeth Araujo¹ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti- citrullinated protein antibodies (ACPA) are known to be associated with joint destruction and a more severe disease course in rheumatoid arthritis (RA) patients.…
Abstract Number: 1193 • 2012 ACR/ARHP Annual Meeting
Podoplanin Expression in Rheumatoid Stroma Correlates with Lymphoid Neogenesis and Is Downregulated by Anti-TNF-α Therapy
Regina Faré¹, Elena Izquierdo¹, Manuel J. Del Rey¹, Raquel Celis², Alicia Usategui¹, Juan D. Cañete³ and Jose L. Pablos¹, ¹Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, ²Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Hospital Clínic of Barcelona. IDIBAPS. University of Barcelona, Barcelona, Spain
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) expand and undergo phenotypic changes that contribute to chronic inflammation and joint destruction. Podoplanin (Pdp) is a…
Abstract Number: 2156 • 2012 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Protein Antibodies As a Predictor of Response to Tocilizumab in Patients with Rheumatoid arthritis A Prospective Study
Kensuke Kume¹, Kanzo Amano¹, Susumu Yamada¹, Kuniki Amano², Kazuhiko Hatta³, Hiroyuki Ohta⁴ and Noriko Kuwaba⁵, ¹Rheumatology, Hiroshima Clinic, Hiroshima, Japan, ²Rheumatology, Sky Clinic, Hiroshima, Japan, ³Rheumatology, Hatta Clinic, Kure, Japan, ⁴Medical Research, hiroshima clinic, Hiroshima, Japan, ⁵Medical Research, Sanki Clinical Link, Hiroshima, Japan
Background/Purpose: Tocilizumab, interleukin-6 receptor antibody is very effective in patients with rheumatoid arthritis (RA). Anti-cyclic citrullinated protein antibodies (ACPA) are highly specific and sensitive for…
Abstract Number: 1010 • 2012 ACR/ARHP Annual Meeting
Bone Loss Before Clinical Onset of Rheumatoid Arthritis o Subjects with Anti-Citrullinated Protein Antibodies
Stephanie Finzel¹, Veronika Lang², Arnd Kleyer¹, Juergen Rech³, Bernhard Manger¹, Elizabeth Araujo¹, Axel J. Hueber⁴, Ulrike Harre⁵ and Georg Schett¹, ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Dept. of Medicine, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Institute for Clinical Immunology, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a major risk factor for rapid disease progression in rheumatoid arthritis (RA). We have recently shown that ACPA directly…
Abstract Number: 2130 • 2012 ACR/ARHP Annual Meeting
Studies of Disease and Therapy-Response Biomarkers in Early Rheumatoid Arthritis Treated with Methotrexate
Aase Haj Hensvold¹, Saedis Saevarsdottir*², Wanyiang Li*³, Vivianne Malmström⁴, Guy Cavet⁵, Lars Klareskog⁶ and Anca Catrina¹, ¹Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ²Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc. 341 Oyster Point Blvd South San Francisco, CA 94080, San Francisco, CA, ⁴Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Crescendo Bioscience Inc., South San Francisco, CA, ⁶Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
*equally contributed Background/Purpose: To identify disease and therapy response serum biomarkers in early untreated RA patients started on methotrexate as the only DMARD. Methods: 186…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
Abstract Number: 973 • 2012 ACR/ARHP Annual Meeting
New Genetic Risk Loci for the Radiographic Severity of Rheumatoid Arthritis
Diederik P.C. de Rooy¹, Sacha Zhernakova¹, Roula Tsonaka², Fina Kurreeman³, René E.M. Toes¹, Tom W. J. Huizinga⁴, Jeanine Houwing-Duistermaat⁵, Peter K. Gregersen⁶ and Annette H.M. van der Helm-van Mil¹, ¹Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Medical Statistics, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Rheumatology, Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Statistics, Statistics, Leiden University Medical Center, Leiden, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: The severity of joint destruction is highly variable between Rheumatoid Arthritis (RA) patients; approximately 54% of this variance is explained by genetic factors. Many…
Abstract Number: 2116 • 2012 ACR/ARHP Annual Meeting
The Associations of HLA-DR Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis
Mehret Birru Talabi¹, Rachel Mackey², Larry W. Moreland³, Jan Dorman⁴, Kevin D. Deane⁵, Jeremy Sokolove⁶, V. Michael Holers⁷, William H. Robinson⁸, Brian Wallitt⁹ and Lewis Kuller¹⁰, ¹Department of Internal Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁴School of Nursing, University of Pittsburgh School of Nursing, Pittsburgh, PA, ⁵Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ⁶Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁷Rheumatology Division, University of Colorado School of Medicine, Aurora, CO, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Washington Hospital Center, Baltimore, MD, ¹⁰Epidemiology, University of Pittsburgh, Pittsburgh, PA
Title: The Associations of HLA-DRβ1 Shared Epitope Alleles and Serum Cytokines Among Postmenopausal Women with Rheumatoid Factor and Anti-Citrullinated Protein Antibody-Positive Rheumatoid ArthritisBackground/Purpose: This study…
Abstract Number: 436 • 2012 ACR/ARHP Annual Meeting
Synthetic Anti-CCP Antibody Aggravated Severity of Animal Arthritis and Captured Citrullinated Antigen in the Serum of Patients with Rheumatoid Arthritis
Youngkyun Kim¹, Su-Jin Moon², Hyoju Yi² and Ji Hyeon Ju³, ¹1Convergent Research Consortium for Immunologic Disease, The Catholic University of Korea, Seoul, South Korea, ²Rheumatology, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ³Rheumatology, College of Medicine, The Catholic University of Korea & Stanford University, Seoul & Palo Alto, CA
Background/Purpose: Auto-antibodies against citrullinated protein antigens (ACPA) have shown their relevance for the prognosis and diagnosis of rheumatoid arthritis (RA), and have been implicated in…
Abstract Number: 2120 • 2012 ACR/ARHP Annual Meeting
Predictive Value of Anti-CCP Positivity On Disease Course and Response to Therapy in Early Rheumatoid Arthritis. Results From the Swedish EIRA Study
Saedis Saevarsdottir¹, Marie Holmqvist², Johan Askling³, Lars Alfredsson⁴ and Lars Klareskog⁵, ¹Rheumatology Unit, Dept. of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine, Rheumatology Unit & Clinical Epidemiology Unit, Karolinska Institute, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Karolinska Institute, Stockholm, Sweden
Background/Purpose: Does anti-CCP-positivity predict disease course and response to therapy in early rheumatoid arthritis (RA)? Methods: We retrieved clinical follow-up data for patients entering the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].